NASDAQ Framework: Bruker Corporation

Scientific instruments and diagnostic solutions provider 1.

Bruker Corporation, headquartered in Billerica, Massachusetts, develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions globally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies, with the BSI CALID segment generating the maximum revenue. Bruker’s high-performance instruments and solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels, supporting innovation and productivity in various fields, including life science molecular research, applied and pharma applications, and clinical microbiology. The company is committed to advancing state-of-the-art technologies and meeting customers' needs across over 90 locations worldwide 2 3 4 5.

2: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific. View Source3: Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. View Source4: Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. View Source5: Today, worldwide more than 9700 employees are working on this permanent challenge at over 90 locations on all continents. Bruker continues to build upon its extensive range of products and solutions, its broad base of installed systems and a strong reputation among its customers. Being one of the world's leading analytical instrumentation companies, Bruker is strongly committed to further fully meet its customers’ needs as well as to continue to develop state-of-the-art technologies and innovative solutions for today's analytical questions. View Source

NO

There is no information provided indicating that Bruker Corporation is still led by its founders or that the founders are heavily involved 6.

6: Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. View Source

LOW RISK

Bruker Corporation appears to be in a stable financial situation. The company has a diverse product portfolio and operates across multiple segments, generating maximum revenue from the BSI CALID segment 7. Additionally, Bruker has a strong market presence globally, with over 9700 employees and operations in more than 90 locations 8. The company’s market capitalization stands at $9.42 billion, and it has a reasonable price-to-earnings ratio of 22.71, with a forward P/E of 19.95, indicating investor confidence in its future earnings 9. Furthermore, Bruker continues to innovate and expand its product offerings, as evidenced by recent launches and successful installations 10 11 12. These factors collectively suggest that Bruker Corporation is financially sound and capable of covering its costs and spending plans.

7: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific. View Source8: Today, worldwide more than 9700 employees are working on this permanent challenge at over 90 locations on all continents. Bruker continues to build upon its extensive range of products and solutions, its broad base of installed systems and a strong reputation among its customers. Being one of the world's leading analytical instrumentation companies, Bruker is strongly committed to further fully meet its customers’ needs as well as to continue to develop state-of-the-art technologies and innovative solutions for today's analytical questions. View Source9: The stock’s market cap achieved a total value of $9.42 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Bruker Corp (NASDAQ:BRKR) is 22.71. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 19.95. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3.14 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.39, which equates the market value of a stock with its book value. View Source10: Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately Business Wire Jul 18, 2024 11:00am Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin Business Wire Jul 2, 2024 11:00am Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories Business Wire Jun 3, 2024 11:00am Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics Business Wire Jun 3, 2024 11:00am Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications Business Wire Jun 3, 2024 11:00am Bruker Corporation to Present at Upcoming Investor Conferences Business Wire May 31, 2024 8:05pm Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference GlobeNewswire May 30, 2024 1:15pm Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024 GlobeNewswire May 30, 2024 1:15pm View Source11: July 02, 2024 Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin BERLIN, Germany – July 2nd, 2024 – Bruker is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research. Read More View Source12: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source

YES

Bruker Corporation is launching new product offerings. Recent announcements include the launch of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) for metal analysis 13, the neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) applications 14, and the timsTOF Ultra 2 mass spectrometer for single-cell and subcellular proteomics 15.

13: June 07, 2024 Bruker Introduces the Q6 NEWTON™ OES Benchtop Solution for Metal Analysis KARLSRUHE, Germany – June 7, 2024 – Bruker, a global leader in analytical instrumentation, announces the launch of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) designed to greatly improve alloy composition analysis in the metals industry. With its cutting-edge features and performance, the Q6 NEWTON empowers metallurgists and technicians to achieve precision, speed, and reliability like never before with a benchtop instrument. Read More View Source14: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source15: Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately Business Wire Jul 18, 2024 11:00am Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin Business Wire Jul 2, 2024 11:00am Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories Business Wire Jun 3, 2024 11:00am Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics Business Wire Jun 3, 2024 11:00am Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications Business Wire Jun 3, 2024 11:00am Bruker Corporation to Present at Upcoming Investor Conferences Business Wire May 31, 2024 8:05pm Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference GlobeNewswire May 30, 2024 1:15pm Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024 GlobeNewswire May 30, 2024 1:15pm View Source

Bruker Corporation's product roadmap and expansion strategy for 2024 through to 2026 focus on launching innovative high-performance scientific instruments and expanding their market presence globally. Key initiatives include the introduction of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) for metal analysis, the neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) applications, and the timsTOF Ultra 2 mass spectrometer for single-cell and subcellular proteomics 16 17 18. Additionally, Bruker has successfully installed a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, positioning itself at the forefront of biomolecular research 19. The company continues to showcase its latest innovations at major conferences, such as ASMS 2024, highlighting its commitment to advancing research and analysis in applied laboratories 20.

16: June 07, 2024 Bruker Introduces the Q6 NEWTON™ OES Benchtop Solution for Metal Analysis KARLSRUHE, Germany – June 7, 2024 – Bruker, a global leader in analytical instrumentation, announces the launch of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) designed to greatly improve alloy composition analysis in the metals industry. With its cutting-edge features and performance, the Q6 NEWTON empowers metallurgists and technicians to achieve precision, speed, and reliability like never before with a benchtop instrument. Read More View Source17: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source18: Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics View Source19: July 02, 2024 Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin BERLIN, Germany – July 2nd, 2024 – Bruker is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research. Read More View Source20: June 3, 2024 Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories ANAHEIM, California – June 3, 2024: The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024: • New EVOQ® DART-TQ+ system for chromatography-free triple-quadrupole mass spectrometry for point-of-need (PoN) routine analysis • Launch of novel ecTOF™ with simultaneous EI and CI ionization in TOF high-resolution mass spectrometry, for ultimate confidence in compound identification with GC-HRMS Read More View Source

Sources

1: Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. View Source2: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific. View Source3: Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. View Source4: Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. View Source5: Today, worldwide more than 9700 employees are working on this permanent challenge at over 90 locations on all continents. Bruker continues to build upon its extensive range of products and solutions, its broad base of installed systems and a strong reputation among its customers. Being one of the world's leading analytical instrumentation companies, Bruker is strongly committed to further fully meet its customers’ needs as well as to continue to develop state-of-the-art technologies and innovative solutions for today's analytical questions. View Source6: Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. View Source7: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific. View Source8: Today, worldwide more than 9700 employees are working on this permanent challenge at over 90 locations on all continents. Bruker continues to build upon its extensive range of products and solutions, its broad base of installed systems and a strong reputation among its customers. Being one of the world's leading analytical instrumentation companies, Bruker is strongly committed to further fully meet its customers’ needs as well as to continue to develop state-of-the-art technologies and innovative solutions for today's analytical questions. View Source9: The stock’s market cap achieved a total value of $9.42 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Bruker Corp (NASDAQ:BRKR) is 22.71. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 19.95. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3.14 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.39, which equates the market value of a stock with its book value. View Source10: Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately Business Wire Jul 18, 2024 11:00am Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin Business Wire Jul 2, 2024 11:00am Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories Business Wire Jun 3, 2024 11:00am Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics Business Wire Jun 3, 2024 11:00am Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications Business Wire Jun 3, 2024 11:00am Bruker Corporation to Present at Upcoming Investor Conferences Business Wire May 31, 2024 8:05pm Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference GlobeNewswire May 30, 2024 1:15pm Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024 GlobeNewswire May 30, 2024 1:15pm View Source11: July 02, 2024 Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin BERLIN, Germany – July 2nd, 2024 – Bruker is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research. Read More View Source12: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source13: June 07, 2024 Bruker Introduces the Q6 NEWTON™ OES Benchtop Solution for Metal Analysis KARLSRUHE, Germany – June 7, 2024 – Bruker, a global leader in analytical instrumentation, announces the launch of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) designed to greatly improve alloy composition analysis in the metals industry. With its cutting-edge features and performance, the Q6 NEWTON empowers metallurgists and technicians to achieve precision, speed, and reliability like never before with a benchtop instrument. Read More View Source14: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source15: Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately Business Wire Jul 18, 2024 11:00am Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin Business Wire Jul 2, 2024 11:00am Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories Business Wire Jun 3, 2024 11:00am Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics Business Wire Jun 3, 2024 11:00am Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications Business Wire Jun 3, 2024 11:00am Bruker Corporation to Present at Upcoming Investor Conferences Business Wire May 31, 2024 8:05pm Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference GlobeNewswire May 30, 2024 1:15pm Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024 GlobeNewswire May 30, 2024 1:15pm View Source16: June 07, 2024 Bruker Introduces the Q6 NEWTON™ OES Benchtop Solution for Metal Analysis KARLSRUHE, Germany – June 7, 2024 – Bruker, a global leader in analytical instrumentation, announces the launch of the Q6 NEWTON™ benchtop spark Optical Emission Spectrometer (OES) designed to greatly improve alloy composition analysis in the metals industry. With its cutting-edge features and performance, the Q6 NEWTON empowers metallurgists and technicians to achieve precision, speed, and reliability like never before with a benchtop instrument. Read More View Source17: June 3, 2024 Bruker Launches Transformative neofleXTM MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications ANAHEIM, California– June 3rd, 2024 – At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. Read More View Source18: Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics View Source19: July 02, 2024 Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin BERLIN, Germany – July 2nd, 2024 – Bruker is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research. Read More View Source20: June 3, 2024 Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories ANAHEIM, California – June 3, 2024: The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024: • New EVOQ® DART-TQ+ system for chromatography-free triple-quadrupole mass spectrometry for point-of-need (PoN) routine analysis • Launch of novel ecTOF™ with simultaneous EI and CI ionization in TOF high-resolution mass spectrometry, for ultimate confidence in compound identification with GC-HRMS Read More View Source